Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
1.320
+0.000 (+0.01%)
Streaming Delayed Price
Updated: 10:47 AM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
30
31
Next >
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Confident that 2023 will be Lexaria’s Best Year Ever
April 03, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’
March 24, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Drug Delivery Technology Demonstrates Growing List of Potential Applications as Evidenced Through Numerous R&D Programs
March 24, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs
March 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD
March 17, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD
March 17, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes
March 14, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension
March 10, 2023
Via
Investor Brand Network
Exposures
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories
March 08, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories
March 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology
March 07, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
March 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
March 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
March 02, 2023
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in
Via
Benzinga
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
March 02, 2023
Via
ACCESSWIRE
$1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying
February 28, 2023
The Dow Jones closed lower by over 70 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested...
Via
Benzinga
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD
February 27, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking Forward to 2023 Goals for Patented DehydraTECH(TM) Technology
February 23, 2023
Via
Investor Brand Network
Topics
Economy
Exposures
Economy
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study
February 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Findings from Hypertension Study
February 21, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD
February 21, 2023
Via
Benzinga
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
February 21, 2023
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities
February 21, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities
February 21, 2023
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin
February 17, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin
February 17, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels
February 10, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels
February 10, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study
February 10, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform
February 08, 2023
Via
Investor Brand Network
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.